

## Freedom of Information Request

---

Reference Number: [EPUT.FOI.22.2453](#)

Date Received: [1 April 2022](#)

---

### Information Requested:

1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
  - Abemaciclib (Verzenios) + aromatase inhibitor \*
  - Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
  - Alpelisib (Piqray) + Fulvestrant (Faslodex)
  - Atezolizumab (Tecentriq)\*\*
  - Bevacizumab (Avastin)
  - Eribulin (Halaven)
  - Everolimus (Afinitor) + Exemestane
  - Fulvestrant (Faslodex) as a single agent
  - Gemcitabine + paclitaxel
  - Herceptin (Trastuzumab) + paclitaxel
  - Herceptin (Trastuzumab) as a single agent
  - Lapatinib (Tyverb)
  - Neratinib (Nerlynx)
  - Olaparib (Lynparza)
  - Palbociclib (Ibrance) + aromatase inhibitor\*
  - Palbociclib (Ibrance) + Fulvestrant (Faslodex)
  - Pertuzumab (Perjeta) + trastuzumab + docetaxel
  - Ribociclib (Kisqali) + aromatase inhibitor\*
  - Ribociclib (Kisqali) + Fulvestrant (Faslodex)
  - Talazoparib (Talzenna)

- Trastuzumab emtansine (Kadcyla)
- Other active systemic anti-cancer therapy \*\*

\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent

2. For the above patients, how many of these received their first ever dose for each product line?

---

**Response:**

Essex Partnership University NHS Foundation Trust is a Mental Health, Learning Disability and Community Services Trust and does not offer these services.

---

**Publication Scheme:**

As part of the Freedom of Information Act all public organisations are required to proactively publish certain classes of information on a Publication Scheme. A publication scheme is a guide to the information that is held by the organisation. EPUT's Publication Scheme is located on its Website at the following link <https://eput.nhs.uk>